Carsten Nieder1,2, Johannes A Langendijk3, Matthias Guckenberger4, Anca L Grosu5. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, 8092, Bodø, Norway. carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, 9038, Tromsø, Norway. carsten.nieder@nlsh.no. 3. Department of Radiation Oncology, University Medical Centre Groningen, 9713, Groningen, The Netherlands. 4. Department of Radiation Oncology, University Hospital Zürich, 8091, Zürich, Switzerland. 5. Department of Radiation Oncology, University Hospital Freiburg, 79106, Freiburg, Germany.
Abstract
BACKGROUND: Reirradiation is a potentially useful option for many patients with recurrent cancer. The purpose of this study was to review all recently published randomized trials in order to identify methodological strengths and weaknesses, comment on the results, clinical implications and open questions, and give advice for the planning of future trials. MATERIALS AND METHODS: Systematic review of trials published between 2000 and 2015 (databases searched were PubMed, Scopus and Web of Science). RESULTS: We reviewed 9 trials, most of which addressed reirradiation of head and neck tumours. The median number of patients was 69. Trial design, primary endpoint and statistical hypotheses varied widely. The results contribute mainly to decision making for reirradiation of nasopharynx cancer and bone metastases. The trials with relatively long median follow-up confirm that serious toxicity remains a concern after high cumulative total doses. CONCLUSION: Multi-institutional collaboration is encouraged to complete sufficiently large trials. Despite a paucity of large randomized studies, reirradiation has been adopted in different clinical scenarios by many institutions. Typically, the patients have been assessed by multidisciplinary tumour boards and advanced technologies are used to create highly conformal dose distributions.
BACKGROUND: Reirradiation is a potentially useful option for many patients with recurrent cancer. The purpose of this study was to review all recently published randomized trials in order to identify methodological strengths and weaknesses, comment on the results, clinical implications and open questions, and give advice for the planning of future trials. MATERIALS AND METHODS: Systematic review of trials published between 2000 and 2015 (databases searched were PubMed, Scopus and Web of Science). RESULTS: We reviewed 9 trials, most of which addressed reirradiation of head and neck tumours. The median number of patients was 69. Trial design, primary endpoint and statistical hypotheses varied widely. The results contribute mainly to decision making for reirradiation of nasopharynx cancer and bone metastases. The trials with relatively long median follow-up confirm that serious toxicity remains a concern after high cumulative total doses. CONCLUSION: Multi-institutional collaboration is encouraged to complete sufficiently large trials. Despite a paucity of large randomized studies, reirradiation has been adopted in different clinical scenarios by many institutions. Typically, the patients have been assessed by multidisciplinary tumour boards and advanced technologies are used to create highly conformal dose distributions.
Authors: Vassilis E Kouloulias; George A Plataniotis; John R Kouvaris; Costas E Dardoufas; Costas Gennatas; Willy Landuyt; Kiki Pistevou-Gompaki; Lambros J Vlahos Journal: Cancer Lett Date: 2003-04-10 Impact factor: 8.679
Authors: Wolfgang Wick; Harald Fricke; Klaus Junge; Grigory Kobyakov; Tobias Martens; Oliver Heese; Benedikt Wiestler; Maximilian G Schliesser; Andreas von Deimling; Josef Pichler; Elena Vetlova; Inga Harting; Jürgen Debus; Christian Hartmann; Claudia Kunz; Michael Platten; Martin Bendszus; Stephanie E Combs Journal: Clin Cancer Res Date: 2014-10-22 Impact factor: 12.531
Authors: Corey J Langer; Jonathan Harris; Eric M Horwitz; Nicos Nicolaou; Merrill Kies; Walter Curran; Stuart Wong; Kian Ang Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: B Emami; C Scott; C A Perez; S Asbell; P Swift; P Grigsby; A Montesano; P Rubin; W Curran; J Delrowe; H Arastu; K Fu; E Moros Journal: Int J Radiat Oncol Biol Phys Date: 1996-03-15 Impact factor: 7.038
Authors: Fu Jin; Huan-Li Luo; Juan Zhou; Ya-Nan He; Xian-Feng Liu; Ming-Song Zhong; Han Yang; Chao Li; Qi-Cheng Li; Xia Huang; Xiu-Mei Tian; Da Qiu; Guang-Lei He; Li Yin; Ying Wang Journal: Cancer Manag Res Date: 2018-06-22 Impact factor: 3.989
Authors: Eric D Miller; Feifei Song; Jason D Smith; Ahmet S Ayan; Xiaokui Mo; Michael Weldon; Lanchun Lu; Phil G Campbell; Aashish D Bhatt; Arnab Chakravarti; Naduparambil K Jacob Journal: Wound Repair Regen Date: 2018-12-21 Impact factor: 3.617
Authors: Alexander Rühle; Tanja Sprave; Tobias Kalckreuth; Raluca Stoian; Erik Haehl; Constantinos Zamboglou; Roland Laszig; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay Journal: Radiat Oncol Date: 2020-04-16 Impact factor: 3.481